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AbstrAct
Introduction Adherence to immunosuppressant 
medication is essential for renal transplant recipients. 
This review aims to summarise what is known about 
non-adherence, with a view to providing comprehensive 
evidence to inform strategies aimed at advancing adherent 
behaviour.
Methods and analysis A systematic review 
of quantitative studies that report adherence to 
immunosuppressants in adult (over 18 years) renal 
transplant recipients. The review will follow the PRISMA 
(Preferred Reporting Items for Systematic Reviews and 
Meta-analyses) guidelines; study quality will be assessed 
using the Downs and Black checklist. Systematic 
searches will be completed across relevant databases. 
Two reviewers will independently extract data using a 
predefined data extraction form. We will summarise the 
operationalisation of adherence across studies and use 
narrative synthesis to identify factors associated with non-
adherence. A meta-analysis will be conducted if there is 
sufficient homogeneity, and available data, across studies 
to estimate the prevalence of non-adherence in renal 
transplant recipients. Heterogeneity will be assessed using 
the I2 test. Survival analysis will be conducted to estimate 
hazard ratios to explore the impact of non-adherence on 
graft survival, graft failure and patient survival.
Ethics and dissemination Findings will be published in 
a peer-reviewed journal and disseminated at conferences 
for professionals and researchers. Review outcomes will 
help support clinical practice by highlighting the extent of 
non-adherence among adults, and in doing so, signpost 
the need for suitable intervention.
trial registration number PROSPERO registration 
number (CRD42016038751).
IntroductIon
Chronic kidney disease (CKD) is a long-
term condition characterised by progres-
sive decline in kidney function over time1 
and often occurs in association with other 
illnesses.2 End-stage renal disease (ESRD) 
occurs within stage five CKD, at which point 
patients require renal replacement therapy 
(RRT) in order to survive. For the majority 
of patients, kidney transplantation is the best 
and most cost-effective option.3 At the end 
of 2012, 55 000 patients were receiving RRT 
in the UK, with 50% having a functioning 
kidney transplant.4
Renal transplant patients must take immu-
nosuppressant medication to prevent rejec-
tion of the organ.5 A combination of two 
or three different immunosuppressants are 
taken on a long-term basis to prevent rejec-
tion; however, as with all medications, patients 
can experience side effects.6 This can include 
an increased risk of infection, diabetes, 
increased susceptibility to certain types of 
cancers, increased blood pressure and weight 
gain.7 It is also true that the process of immu-
nosuppression itself may add to the burden 
of comorbidity.8 Despite the nuances of medi-
cation, adherence to the immunosuppressive 
regimen is vital to provide the kidney with the 
best chance of survival and function following 
transplantation.
Adherence in this context refers to ‘the 
extent to which the patient’s behaviour 
matches agreed recommendations from the 
prescriber’.9 Adherence can be measured 
in a number of different ways, including 
self-report, observation of medication intake, 
reports from clinicians and electronic moni-
toring.10 Electronic monitoring is regarded 
as the most accurate option for measuring 
adherence in research as it is both a sensitive 
Non-adherence to immunosuppressants 
following renal transplantation: a 
protocol for a systematic review
Abigail Hucker,1 Frances Bunn,2 Lewis Carpenter,1 Christopher Lawrence,3 
Ken Farrington,3 Shivani Sharma1
To cite: Hucker A, 
Bunn F, Carpenter L, 
et al.  Non-adherence to 
immunosuppressants following 
renal transplantation: a 
protocol for a systematic 
review. BMJ Open 
2017;7:e015411. doi:10.1136/
bmjopen-2016-015411
 ► Prepublication history for 
this paper is available online. 
To view these files please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2016- 
015411).
Received 14 February 2017
Revised 9 May 2017
Accepted 2 June 2017
1Department of Psychology and 
Sport Sciences, School of Life 
and Medical Sciences, University 
of Hertfordshire, Hatfield, UK
2Centre for Research in Primary 
and Community Care, University 
of Hertfordshire, Hatfield, UK
3Renal Unit, Lister Hospital, 
Stevenage, Hertfordshire, UK
correspondence to
Dr Shivani Sharma;  
 s. 3. sharma@ herts. ac. uk
Protocol
strengths and limitations of this study
 ► Adherence to immunosuppressant medication is 
essential for renal transplant recipients; however, 
there is a need for an up-to-date synthesis of current 
evidence on non-adherence in this group.
 ► Findings from this review could help inform patient 
information needs and the design and delivery of 
psychosocial support to improve adherence for renal 
transplant recipients.
 ► This review will only include studies conducted in 
English due to the complexity involved in translation 
of papers.
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and objective measure.10 However, self-reported non-ad-
herence has been shown to be strongly predictive of 
adherence measured by electronic monitoring, and 
therefore useful for identifying patients at greater risk for 
non-adherence in clinical practice.11
Non-adherence to immunosuppressive medication is 
a major risk factor for poor clinical outcomes post-trans-
plantation; however, it remains a common issue in 
this patient population, identified as the second most 
common cause of late graft failure in renal transplant 
patients.12 A review based on 38 articles13 estimated that 
the rate of non-adherence lies between 28% and 52%. In 
a meta-analysis, the odds of graft failure were seven times 
greater in non-adherent patients compared with adherent 
patients.14 Factors identified as determinants of non-ad-
herence post-transplant14 were consistent with more 
recent literature, such as younger age, being unmarried 
and perceiving low social support,11 13 high emotional 
distress and high transplant-related stress.15 In addition 
to this, having a donor graft from a living relative has 
also been identified as a risk factor for non-adherence.11 
Furthermore, ill health resulting from non-adherence is 
costly for the National Health Service (NHS), since dial-
ysis services are considerably more expensive than those 
required to support a functioning transplant.15 Moreover, 
a prerequisite for optimal adherence is access to treat-
ment; however, previous literature has highlighted that 
cost-related non-adherence is an issue among renal trans-
plant recipients in localities such as the USA, as patients 
do not benefit from insurance coverage to support access 
to immunosuppressive medication, and are therefore at 
greater risk of graft failure.16
There are a number of reasons why patients may 
not adhere to their immunosuppressant regimen. In 
addition to those mentioned above, unintentional and 
intentional non-adherence have been identified as 
issues in this patient population. Unintentional non-ad-
herence is significantly more common than inten-
tional non-adherence,17 and most commonly occurs 
when patients find themselves outside of their normal 
daily routine. In contrast, intentional non-adherence 
occurs when patients have concerns about their medi-
cation regimen. Psychological distress, notably anxiety, 
hostility and depression have been identified as having 
an impact on medication adherence,18 with depression 
also being associated with higher intentional non-ad-
herence.17 In addition, non-adherent patients have a 
greater symptom burden, higher distress levels19 and 
report higher frequency of stress.20 Hence, renal trans-
plant recipients may require a range of supports to help 
them maintain a lifestyle associated with their health 
status. A recent systematic review evaluated interven-
tions to improve medication adherence in adult renal 
transplant patients,21 suggesting that those targeting 
behavioural risk factors or multidimensional inter-
ventions22 23 combining educational, behavioural and 
emotional factors are more likely to be effective in 
improving non-adherence to medication.
Clearly non-adherence to immunosuppressive medica-
tion is common and a major risk factor for poor outcomes 
post-transplantation. The consequences of non-adher-
ence are far reaching for patients in terms of reduced 
health-related quality of life and survival. Added to this 
they entail a significant cost burden-related to increased 
care needs.16 There are two core reviews available, 
published in 200315 and 200414 which aim to highlight 
the extent of non-adherence in this patient group. It is 
fair to say, though that progressive recognition of non-ad-
herence in renal care settings has resulted in a larger 
evidence base. A synthesis of the existing body of research 
in the area would therefore be welcome to guide clinical 
practice and to further inform the nature of intervention.
In the light of this, the current paper details proposals 
for a systematic review and meta-analysis that will provide 
the most comprehensive evidence synthesis of what is 
known about non-adherence in adult renal transplant 
recipients. In doing so, the review will:
 ► Summarise the methods used to assess non-adherence 
and discuss how non-adherence is operationalised 
across studies.
 ► Identify the prevalence of non-adherence by pooling 
data from across studies and considering whether 
reported non-adherence varies as a function of meas-
urement source.
 ► Provide a narrative summary of the main factors asso-
ciated with non-adherence.
 ► Estimate the impact of psychological correlates such 
as depression or anxiety and illness perceptions on 
non-adherence.
 ► Estimate the impact of non-adherence on graft failure, 
graft survival and mortality.
MEthods And dEsIgn
This protocol has been written using the PRISMA-P 
(Preferred Reporting Items for Systematic Reviews and 
Meta-analyses Protocols) guidelines and has been regis-
tered on the PROSPERO database (registration number: 
CRD42016038751).
Eligibility criteria
This review will only include English language literature. 
Study inclusion and exclusion criteria are given below.
types of studies
This review will include published peer-reviewed studies 
and grey literature. All quantitative studies that examine 
non-adherence to immunosuppressant’s in renal trans-
plant patients will be included (cross-sectional, cohort 
and case series studies will be included). Randomised 
controlled trials will not be included, as this systematic 
review is not analysing interventions. All studies must 
include a measure of non-adherence.
Participants
This review will include patients aged 18 and over who have 
received a solid organ kidney transplant. Participants will 
be included irrespective of graft function (functioning or 
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Table 1 Search terms
Concept No Search terms
Concept 
1: Population
1 kidney transplantation (MeSH)
2 “kidney transplant*” (free-text 
term)
3 “renal transplant*”(free-text term)
4 OR [1–3]
Concept 2: 
Adherence (outcome)
5 adherence, medication (MeSH)
6 adherence (free-text term)
7 non-adherence (free-text term)
8 noncompliance (free-text term)
9 compliance (free-text term)
10 “treatment refusal” (free-text 
term)
11 “patient compliance” (free-text 
term)
12 “medical compliance” (free-text 
term)
13 “medical adherence” (free-text 
term)
14 “medical non-adherence” (free-
text term)
15 concordan* (free-text term)
16 OR [5–15]
Concept 3:  
Immunosuppression
17 immunosuppression (MeSH)
18 immunosuppress* (free-text 
term)
19 OR [17–18]
All concepts 
combined
20 4 AND 16 AND 19
failed) at the time of entry into the study. Children and 
adolescents will be excluded from this review as evidence 
suggests that different challenges contribute to non-ad-
herence in this group.24
outcomes
Primary outcomes
Studies will be included if one of the outcomes is the 
degree of non-adherence to immunosuppressants. It 
is likely that this will be measured in a number of ways 
including self-report, electronic monitoring of pill bottles 
and observations.
Secondary outcomes
For the studies that meet the primary inclusion criteria, 
the following outcomes will also be assessed if sufficient 
information is available: whether non-adherence is 
intentional or unintentional (forgetting), risk factors for 
non-adherence as reported in the studies, for example, 
age, time since transplantation, comorbidities, psycho-
logical correlates of non-adherence, for example, depres-
sion, illness perceptions, and clinical outcomes such as 
graft failure, graft survival and mortality.
Information sources
Searches will include the following electronic data-
bases: PubMed, Scopus, CINAHL, The Cochrane library, 
PsychARTICLES and Google scholar. There will be no 
date limits on the searches in all. In addition, lateral 
search techniques will be used, such as checking refer-
ence lists for related articles and using Google scholar to 
conduct key word and citation searches. Furthermore, 
contact with experts in the field will identify grey litera-
ture and ongoing studies.
search strategy
A combination of free text terms and medical subject 
heading (MeSH) search terms will be used in all databases. 
The search strategy to be used in PubMed is included in 
table 1. This will be adapted accordingly to the subject 
headings of the remaining databases.
study screening and selection process
Citations from all database searches will be imported into 
Endnote reference management software. A check will be 
run to identify, note and remove any duplicate citations.
Retrieved records will be screened by title and abstract 
by two reviewers independently in order to assess suit-
ability for inclusion. Any disagreements will be resolved 
by discussion or consultation with a third reviewer. 
Full texts of potentially relevant citations will be inde-
pendently assessed for inclusion in the review using a 
piloted screening proforma. A second reviewer will inde-
pendently screen 25% of the titles and abstracts and full 
texts for quality assurance. If any relevant information 
on eligibility is missing, study authors will be contacted. 
Reasons for excluding studies will be recorded.
data collection process
A data extraction form will be used to extract the rele-
vant information from each study to be included in the 
review. The form will be created in Microsoft Excel. Two 
reviewers will independently extract the relevant infor-
mation from the full text papers into the data extraction 
table. This will be pilot tested on a few studies prior to the 
review to ensure consistency between the two reviewers 
and to ensure the correct information has been included. 
The use of two reviewers for data extraction will be used 
to reduce the risk of error. Any disagreement will be 
resolved by discussion with a third reviewer.
data items
Data will be extracted using the following categories:
 ► General information: date of data extraction, study 
title, author and year of publication, country of origin
 ► Study methods/characteristics: study design 
(including how adherence was defined and meas-
ured), study aims and research questions, inclusion/
exclusion criteria, sampling methods
group.bmj.com on February 22, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
4 Hucker A, et al. BMJ Open 2017;7:e015411. doi:10.1136/bmjopen-2016-015411
Open Access 
 ► Demographics about the participants (age, sex, 
ethnicity, socio-economic characteristics)
 ► Number of non-adherent patients
 ► Number of transplants
 ► Outcomes of the study, correlates and any other clin-
ical measures (such as graft survival, number of graft 
failures (assessed as caused by non-adherence) and 
mortality/survival)
outcomes and prioritisation
The primary outcome will be the degree of non-adher-
ence to immunosuppressants. For studies that meet the 
primary inclusion criteria, the following outcomes will also 
be assessed if available: whether non-adherence is inten-
tional or unintentional (eg, forgetting), which is likely to 
be reported via self-report; psychological correlates such 
as depression or anxiety (measured using any validated 
scale); illness perceptions; clinical outcomes (eg, graft 
rejection, graft failure and mortality).
risk of bias in individual studies
Studies will be rated for quality assurance using the Downs 
and Black25 checklist for non-randomised studies, case–
control, cross-sectional and cohort studies. This consists 
of five domains: study quality, external validity, study 
bias, confounding and selection bias and study power. 
One reviewer (AH) will rate all the studies, and a second 
reviewer will independently rate 25% of the studies 
chosen at random. Any discrepancies between reviewers 
will be resolved by discussion with a third reviewer.
data synthesis
A narrative synthesis will be used to summarise the 
different methods of measuring adherence. In addi-
tion, we will investigate how studies define non-adher-
ence, and whether this is consistent across studies. A 
meta-analysis will also be included in this review, if there 
is sufficient homogeneity across outcomes and available 
data. Where appropriate, we will use meta-analysis to 
pool together study outcomes to assess: (1) the prev-
alence of non-adherence; (2) factors associated with 
non-adherence (such as illness perceptions and depres-
sion); (3) impact of non-adherence on graft survival, 
graft failure and patient survival. Heterogeneity will 
be assessed using the I2 test.26 An I2 value of 25% is 
categorised as low, 50% moderate and 75% high.27 In 
addition, stratified analysis and/or metaregression 
will be conducted to compare measurement methods, 
dependent on the number of categories and number 
of studies within each category. This analysis will be 
conducted using Stata (version 13). As this review 
will include observational studies, we anticipate using 
random effects meta-analysis. It is likely that studies 
will vary due to differences in patient populations, and 
while provisions have been made to account for this 
variability, it is unlikely that this will be controlled for its 
entirety through the use of metaregression or subgroup 
analyses.
Metabias
Stratified analysis or metaregression will be used to 
compare studies that scored high versus those that scored 
low on the Downs and Black quality assessment tool. 
Publication bias will be investigated through the use of 
funnel plots.
confidence in cumulative estimate
The quality of evidence for outcomes will be assessed 
using the ‘Grading of Recommendations Assessment, 
Development and Evaluation’ (GRADE) approach.28 
Quality will be determined as high, moderate, low or very 
low.29
dIscussIon And dIssEMInAtIon
Non-adherence to immunosuppressants is a major risk 
factor for poor outcomes in renal transplant recipients 
and so has gained increasingly more research attention 
as an issue that needs tackling. The findings from this 
systematic review will be disseminated via a variety of 
routes including publication in a peer-reviewed journal, 
conference presentations and through the clinical and 
academic networks of the team. The findings will be used 
to inform researchers and medical professionals about 
the extent of non-adherence in renal transplant recipi-
ents, alongside whether estimates vary depending on how 
information on adherence is sourced. The comprehen-
sive evidence synthesis will also summarise the state of 
knowledge in relation to factors associated with non-ad-
herence and so by bringing together a larger evidence 
base, may be able to better inform strategies aimed at 
enhancing patient’s self-care behaviour. Information 
gleaned from this review could, for example, help inform 
patient information needs and design and delivery of 
psychosocial support to improve adherence, by providing 
an indication of what areas should be targeted to address 
this issue and when.
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